By Source
• Mammalian Source
• Non-Mammalian Source
By Product
• Biosimilars
• Biologics
o Monoclonal antibodies (MABs)
o Recombinant Proteins
o Vaccines
o Antisense, RNAi, & Molecular Therapy
o Others
By Services
• Product Development
o Downstream
o Upstream
• Fill and Finish Operations
• Analytical and QC Testing
• Packaging
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
The market is categorised into source, product, services and region. The source segment is diversified into mammalian source and mon-mammalian source. The mammalian contract manufacturing segment is anticipated to hold the largest biopharmaceutical contract manufacturing market share, and this can be credited to increased acceptance rate of mammalian system for producing biologics. Furthermore, most of the biopharma products currently in the pipeline are expressed by mammalian source. Companies like Charles River and Lonza have heavily invested in expanding their manufacturing facilities of mammalian cell culture for biosimilars and biologics. The product segment is classified into biosimilars and biologics. The biologics segment dominated the market in 2018 and this primarily owing to the massive commercial acceptance of biologics by the market. The service segment is fragmented into process development, fill and finish operations, analytical and QC testing and packaging.